(S)-5-氨基甲基-2-吡咯烷酮 | 145414-31-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: (S)-5-氨基甲基-2-吡咯烷酮
• 中文别名: (S)-5-氨基甲基吡咯烷-2-酮
• 英文名称: (S)-5-(aminomethyl)pyrrolidin-2-one
• 英文别名: (5S)-5-(aminomethyl)pyrrolidin-2-one；(S)-5-aminomethyl-2-pyrrolidone
• CAS: 145414-31-9
• 化学式: C₅H₁₀N₂O
• 分子量: 114.147
• InChiKey: GFOAHABINHRDKL-BYPYZUCNSA-N

物化性质

• 沸点：
  313.9±15.0 °C(Predicted)
• 密度：
  1.076±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.3
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 储存条件：
  2-8°C，干燥

反应信息

• 作为反应物：
  描述：

  (S)-5-氨基甲基-2-吡咯烷酮 在 盐酸 、 potassium hydroxide 作用下， 以 水 为溶剂， 生成 (S)-N⁴,N⁵-di-i-butoxycarbonyl-4,5-diaminovaleric acid
  参考文献：
  名称：

  Synthesis of a series of ω-dimethylaminoalkyl substituted ethylenediamine ligands for use in enantioselective catalysis

  摘要：

  The title compounds H2NCH((CH2)(n)NMe2)CH2NH2 L1-1A (n = 1-4) are efficiently synthesized in enantiopure form. The commercial starting materials, L-asparagine, (S)-5-hydroxymethy1-2-pyrrolidinone, and (S)-6-(((benzyloxy)carbonyI)-amino)-2-((tert-butoxycarbonyl)amino)hexanoic acid, are elaborated in 6-9 standard steps to giye Ll (18% overall), 12 (13%), L3 (36%) and LA (38%) or the corresponding tris(hydrochloric acid) salts [H3NCH((CH2)(n)NHMe2)CH2NH3](3+) 3Cl(-), which are preferable for long term storage. The sequences make use of isobutyl carbamate, Cbz, and Boc protecting groups and Hofmann type rearrangements; the dimethylamino groups are introduced at late stages, either via reductive dimethylations or nucleophilic displacements involving mesylates and HNMe2. L1-L4 chelate to [Co(en)(2)](3+) fragments to give octahedral complexes that catalyze numerous enantioselective reactions. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2015.09.012
• 作为产物：
  描述：

  (S)-(+)-5-羟甲基-2-吡咯烷酮对甲苯磺酸酯 在 sodium azide 、 palladium on activated charcoal 、 氢气 作用下， 以 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 生成 (S)-5-氨基甲基-2-吡咯烷酮
  参考文献：
  名称：

  [EN] TRANSITION METAL COMPLEXES FOR ENANTIOSELECTIVE CATALYSIS OF CARBON-CARBON, CARBON-HETEROATOM, AND CARBON-HYDROGEN BOND FORMING REACTIONS
  [FR] COMPLEXES DE MÉTAL DE TRANSITION POUR LA CATALYSE ÉNANTIOSÉLECTIVE DE RÉACTIONS DE FORMATION DE LIAISONS CARBONE-CARBONE, CARBONE-HÉTÉROATOME ET CARBONE-HYDROGÈNE

  摘要：

  公开号：

  WO2014018978A3

文献信息

• [EN] IMIDAZO [1, 2 - B] PYRIDAZINE - BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND USES THEREOF<br/>[FR] COMPOSÉS À BASE D'IMIDAZO [1, 2-B] PYRIDAZINE, COMPOSITIONS LES COMPRENANT ET UTILISATIONS DE CEUX-CI
  申请人：LEXICON PHARMACEUTICALS INC

  公开号：WO2013134219A1

  公开（公告）日：2013-09-12

  Imidazo[1,2-b]pyridazine-based compounds of the formula (I): are disclosed, wherein R1, R2 and R3 are defined herein. Compositions comprising the compounds and methods of their use to treat, manage and/or prevent diseases and disorders mediated by mediated by adaptor associated kinase 1 activity are also disclosed.

  基于咪唑并[1,2-b]吡啶嗪的化合物的公式（I）被披露，其中R1、R2和R3在此处被定义。还披露了包含这些化合物的组合物以及它们用于治疗、管理和/或预防由适配器相关激酶1活性介导的疾病和紊乱的方法。
• LINKER-DRUG AND ANTIBODY-DRUG CONJUGATE (ADC) EMPLOYING THE SAME
  申请人：Industrial Technology Research Institute

  公开号：US20180169262A1

  公开（公告）日：2018-06-21

  A linker-drug represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof is provided. In formula (I), C is a conjugator, L is a linker unit, D is a toxin unit, and n is an integer ranging from 1 to 4. The structure of the conjugator is represented by formula (II). In formula (II), X is a leaving group, each of R 1 and R 2 is independently a single bond or —NH—, and Z is substituted aryl, heteroaryl, linear alkyl, cycloalkyl, heterocycloalkyl, or a combination thereof. The antibody is conjugated to the linker unit through a cysteine residue of the antibody. An antibody-drug conjugate (ADC) employing the above linker-drug is also provided.

  提供由式（I）表示的连接药物或其药学上可接受的盐或溶剂。在式（I）中，C是一个结合物，L是一个连接单元，D是一个毒素单元，n是一个从1到4的整数。结合物的结构由式（II）表示。在式（II）中，X是一个离去基团，R1和R2中的每一个独立地是一个单键或—NH—，Z是取代芳基、杂环芳基、直链烷基、环烷基、杂环烷基或它们的组合。抗体通过抗体的半胱氨酸残基与连接单元结合。还提供了使用上述连接药物的抗体-药物结合物（ADC）。
• Inhibitors of protein isoprenyl transferases
  申请人：University of Pittsburgh

  公开号：US20020193596A1

  公开（公告）日：2002-12-19

  Compounds having the formula 1 or a pharmaceutically acceptable salt thereof wherein R 1 is (a) hydrogen, (b) loweralkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl-L 2 —, and (i) heterocyclic-L 2 —; R 2 is selected from (a) 2 (b) —C(O)NH—CH(R 14 )—C(O)OR 15 , (c) 3 (d) —C(O)NH—CH(R 14 )—C(O)NHSO 2 R 16 (e) —C(O)NH—CH(R 14 )-tetrazolyl, (f) —C(O)NH-heterocyclic, and (g) —C(O)NH—CH(R 14 )—C(O)NR 17 R 18 ; R 3 is heterocyclic, aryl, substituted or unsubstituted cycloalkyl; R 4 is hydrogen, lower alkyl, haloalkyl, halogen, aryl, arylakyl, heterocyclic, or (heterocyclic)alkyl; L 1 is absent or is selected from (a) —L 4 —N(R 5 )—L 5 —, (b) —L 4 —O—L 5 —, (c) —L 4 —S(O) n —L 5 — (d) —L 4 -L 6 —C(W)—N(R 5 )—L 5 —, (e) —L 4 -L 6 —S(O) m —N(R 5 )—L 5 —, (f) —L 4 —N(R 5 )—C(W)—L 7 -L 5 —, (g) —L 4 —N(R 5 )—S(O) p —L 7 —L 5 —, (h) optionally substituted alkylene, (i) optionally substituted alkenylene, and (j) optionally substituted alkynylene are inhibitors of protein isoprenyl transferases. Also disclosed are protein isoprenyl transferase inhibiting compositions and a method of inhibiting protein isoprenyl transferases.

  具有以下公式的化合物或其药学上可接受的盐，其中R1为(a)氢，(b)较低的烷基，(c)烯基，(d)烷氧基，(e)硫代烷氧基，(f)卤素，(g)卤代烷基，(h)芳基-L2—，以及(i)杂环-L2—；R2从(a)中选择，(b) -C(O)NH-CH(R14)-C(O)OR15，(c)中选择，(d) -C(O)NH-CH(R14)-C(O)NHSO2R16，(e) -C(O)NH-CH(R14)-四唑基，(f) -C(O)NH-杂环，以及(g) -C(O)NH-CH(R14)-C(O)NR17R18；R3为杂环，芳基，取代或未取代的环烷基；R4为氢，较低烷基，卤代烷基，卤素，芳基，芳基烷基，杂环基，或(杂环)烷基；L1为空缺或从(a) -L4-N(R5)-L5-，(b) -L4-O-L5-，(c) -L4-S(O)n-L5-，(d) -L4-L6-C(W)-N(R5)-L5-，(e) -L4-L6-S(O)m-N(R5)-L5-，(f) -L4-N(R5)-C(W)-L7-L5-，(g) -L4-N(R5)-S(O)p-L7-L5-，(h)可选择取代的烷基，(i)可选择取代的烯基，以及(j)可选择取代的炔基是蛋白异戊二烯转移酶的抑制剂。还公开了蛋白异戊二烯转移酶抑制组合物和抑制蛋白异戊二烯转移酶的方法。
• [EN] SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME<br/>[FR] COMPOSÉS 1,1'-BIPHÉNYLE SUBSTITUÉS ET LEURS PROCÉDÉS D'UTILISATION
  申请人：ARBUTUS BIOPHARMA INC

  公开号：WO2021158481A1

  公开（公告）日：2021-08-12

  The present invention includes substituted 1,1'-biphenyl compounds, analogues thereof, and compositions comprising the same. In one aspect, the compounds contemplated in the invention can be used to treat, ameliorate, or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient. In another aspect, the compounds contemplated in the invention can be used to treat, ameliorate, and/or prevent cancer in a patient.

  本发明包括取代的1,1'-联苯化合物，其类似物，以及包含它们的组合物。在一个方面，本发明中考虑的化合物可用于治疗、改善或预防患者体内的乙型肝炎病毒（HBV）和/或丙型肝炎病毒（HDV）感染。在另一个方面，本发明中考虑的化合物可用于治疗、改善和/或预防患者体内的癌症。
• Syntheses, Biological Evaluations, and Mechanistic Studies of Benzo[<i>c</i>][1,2,5]oxadiazole Derivatives as Potent PD-L1 Inhibitors with <i>In Vivo</i> Antitumor Activity
  作者：Liu Liu、Zhiying Yao、Shijun Wang、Tao Xie、Guoqing Wu、Honghan Zhang、Pu Zhang、Yaojun Wu、Haoliang Yuan、Hongbin Sun

  DOI：10.1021/acs.jmedchem.1c00392

  日期：2021.6.24

  A series of novel benzo[c][1,2,5]oxadiazole derivatives were designed, synthesized, and biologically evaluated as inhibitors of PD-L1. Among them, compound L7 exhibited 1.8 nM IC50 value in a homogeneous time-resolved fluorescence (HTRF) assay, which was 20-fold more potent than the lead compound BMS-1016. In the surface plasmon resonance (SPR) assay, L7 bound to human PD-L1 (hPD-L1) with a KD value

  设计、合成了一系列新型苯并[ c ][1,2,5]恶二唑衍生物，并对其作为PD-L1抑制剂进行了生物学评价。其中，化合物L7在均相时间分辨荧光（HTRF）测定中表现出1.8 nM IC 50值，其效力比先导化合物BMS-1016强20倍。在表面等离子共振 (SPR) 测定中， L7与人 PD-L1 (hPD-L1) 结合， KD值为3.34 nM，但未显示与 hPD-1 的任何结合。在基于细胞的共培养测定中， L7阻断 PD-1/PD-L1 相互作用，EC 50值为 375 nM，而BMS-1016的 EC 50值为 2075 nM。此外，化合物L24 （ L7的酯前药）具有口服生物利用度，并且在同基因小鼠和PD-L1人源化小鼠的肿瘤模型中显示出显着的抗肿瘤作用。从机制上讲， L24可能通过促进抗肿瘤免疫而表现出显着的体内抗肿瘤作用。总之，这一系列苯并恶二唑 PD-L1 抑制剂为肿瘤免疫治